Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells

被引：0
|
作者：
Xing-dong Xu
Lan Yang
Li-yun Zheng
Yan-yan Pan
Zhi-fei Cao
Zhi-qing Zhang
Quan-sheng Zhou
Bo Yang
Cong Cao
机构：
[1] the Third Hospital affiliated to Soochow University,Department of General Surgery
[2] the First Affiliated Hospital of Soochow University,Department of Neurology
[3] Cyrus Tang Hematology Center,undefined
[4] Soochow University,undefined
[5] Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience,undefined
[6] Soochow University,undefined
来源：
BMC Cancer | / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
    Richon, V. M.
    BRITISH JOURNAL OF CANCER, 2006, 95 (Suppl 1) : S2 - S6
  • [22] Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
    V M Richon
    British Journal of Cancer, 2006, 95 : S2 - S6
  • [23] In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer
    Cooper, Amy L.
    Greenberg, Victoria L.
    Lancaster, Pamela S.
    van Nagell, John R., Jr.
    Zimmer, Stephen G.
    Modesitt, Susan C.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 596 - 601
  • [24] The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer
    Arnold, Nichole Boyer
    Arkus, Nolhea
    Gunn, Jason
    Korc, Murray
    CLINICAL CANCER RESEARCH, 2007, 13 (01) : 18 - 26
  • [25] Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor:: Effects on gene expression and growth of glioma cells in vitro and in vivo
    Yin, Dong
    Ong, John M.
    Hu, Jinwei
    Desmond, Julian C.
    Kawamata, Norihiko
    Konda, Bindu M.
    Black, Keith L.
    Koeffler, H. Phillip
    CLINICAL CANCER RESEARCH, 2007, 13 (03) : 1045 - 1052
  • [26] The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
    Butler, Lisa M.
    Liapis, Vasilios
    Bouralexis, Stelios
    Welldon, Katie
    Hay, Shelley
    Thai, Le M.
    Labrinidis, Agatha
    Tilley, Wayne D.
    Findlay, David M.
    Evdokiou, Andreas
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) : 944 - 954
  • [27] Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells
    Cheng, Hsueh-Tsen
    Hung, Wen-Chun
    ONCOLOGY REPORTS, 2013, 29 (03) : 1238 - 1244
  • [28] The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells
    Hsi, LC
    Xi, XP
    Lotan, R
    Shureiqi, I
    Lippman, SM
    CANCER RESEARCH, 2004, 64 (23) : 8778 - 8781
  • [29] Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells
    Maiti, Aparna
    Qi, Qianya
    Peng, Xuan
    Yan, Li
    Takabe, Kazuaki
    Hait, Nitai C.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 55 (01) : 116 - 130
  • [30] Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    J Almenara
    R Rosato
    S Grant
    Leukemia, 2002, 16 : 1331 - 1343
12345